RU-23908, Anandron, 5,5-Dimethyl-3-4-nitro-3-(trifluoromethyl)phenyl-2,4-imidazolidinedione
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
MDL number:
PubChem Substance ID:
Pricing and availability is not currently available.




Sanofi Aventis

SMILES string




InChI key


Gene Information

human ... AR(367)

Looking for similar products? Visit Product Comparison Guide


1 g in glass bottle

Biochem/physiol Actions

Nilutamide is an antiandrogen used in the treatment of prostate cancer.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Other Notes

Tandem Mass Spectrometry data independently generated by Scripps Center for Metabolomics is available to view or download in PDF. N8534.pdf Tested metabolites are featured on Scripps Center for Metabolomics METLIN Metabolite Database. To learn more, visit sigma.com/metlin.

Legal Information

LOPAC is a registered trademark of Sigma-Aldrich Co. LLC


Skull and crossbonesHealth hazard

Signal Word


Hazard Statements

Precautionary Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

Hazard Codes


Risk Statement


Safety Statement



UN 2811 6.1 / PGIII

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Richard Choo et al.
International journal of radiation oncology, biology, physics, 75(2), 407-412 (2009-02-13)
To determine the efficacy of a combined approach of postoperative radiotherapy (RT) plus 2-year androgen suppression (AS) for patients with pathologic T3 disease (pT3) and/or positive surgical margins (PSM) after radical prostatectomy (RP). A total of 78 patients with pT3...
E J Dole et al.
The Annals of pharmacotherapy, 31(1), 65-75 (1997-01-01)
To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of nilutamide and to compare this agent with the currently marketed nonsteroidal antiandrogens (i.e., bicalutamide, flutamide) by critically analyzing the published literature. MEDLINE (1980-1995) and CANCERLIT (1991-1995) were searched for English-language...
Olivier Payen et al.
Journal of medicinal chemistry, 51(6), 1791-1799 (2008-02-29)
We present here the first synthesis of organometallic complexes derived from the nonsteroidal antiandrogen nilutamide, bearing a ferrocenyl substituent at position N(1) or at C(5) of the hydantoin ring; for comparison, we also describe the C(5) p-anisyl organic analogue. All...
Jing Yu et al.
Biochemical and biophysical research communications, 353(3), 764-769 (2007-01-02)
Ginsenosides have been shown to stimulate nitric oxide (NO) production in aortic endothelial cells. However, the signaling pathways involved have not been well studied in human aortic endothelial cells. The present study was designed to examine whether purified ginsenoside Rb1...
A Oliver Sartor et al.
Cancer, 112(11), 2393-2400 (2008-04-03)
Antiandrogen withdrawal is a potential therapeutic maneuver for patients with progressive prostate cancer. This study was designed to examine antiandrogen withdrawal effects within the context of a large multi-institutional prospective trial. Eligibility criteria included progressive prostate adenocarcinoma despite combined androgen...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.